Search Results - "Schwandt, P"

Refine Results
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5

    The optimal use of bexarotene in cutaneous T-cell lymphoma by Gniadecki, R., Assaf, C., Bagot, M., Dummer, R., Duvic, M., Knobler, R., Ranki, A., Schwandt, P., Whittaker, S.

    Published in British journal of dermatology (1951) (01-09-2007)
    “…Summary The management goal in cutaneous T‐cell lymphomas (CTCLs) is to improve symptoms and induce remission. Early‐stage disease is generally treated with…”
    Get full text
    Journal Article
  6. 6
  7. 7
  8. 8
  9. 9

    Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion by Assaf, C., Bagot, M., Dummer, R., Duvic, M., Gniadecki, R., Knobler, R., Ranki, A., Schwandt, P., Whittaker, S.

    Published in British journal of dermatology (1951) (01-08-2006)
    “…Summary Bexarotene is an oral retinoid therapy that is effective for the treatment of early and advanced‐stage cutaneous T‐cell lymphoma (CTCL) in patients who…”
    Get full text
    Journal Article
  10. 10

    The importance of reaching lipid targets: statins and the prevention of atherosclerosis by Schwandt, P

    “…To help prevent the development of coronary heart disease (CHD), the European and NCEP guidelines have recommended target cholesterol levels for all…”
    Get more information
    Journal Article
  11. 11

    The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment by Riegger, G., Abletshauser, C., Ludwig, M., Schwandt, P., Widimsky, J., Weidinger, G., Welzel, D.

    Published in Atherosclerosis (01-05-1999)
    “…The primary objective of the present study was to investigate the cholesterol-lowering effect of fluvastatin on the incidence of cardiac events in…”
    Get full text
    Journal Article
  12. 12

    Cholesterol, essential fatty acids, and suicide by Brunner, Jürgen, Parhofer, K G, Schwandt, P, Bronisch, T

    Published in Pharmacopsychiatry (01-01-2002)
    “…Epidemiological and clinical studies have described an association between lower serum cholesterol concentrations and increased suicide risk that is not…”
    Get more information
    Journal Article
  13. 13

    Parameters of childhood obesity and their relationship to cardiovascular risk factors in healthy prepubescent children by GEISS, H. C, PARHOFER, K. G, SCHWANDT, P

    Published in International Journal of Obesity (01-06-2001)
    “…To investigate which of the currently applied parameters to assess childhood overweight best predict cardiovascular risk factors. Cross-sectional study…”
    Get full text
    Journal Article
  14. 14
  15. 15

    Influence of LDL apheresis on LDL subtypes in patients with coronary heart disease and severe hyperlipoproteinemia by Schamberger, B M, Geiss, H C, Ritter, M M, Schwandt, P, Parhofer, K G

    Published in Journal of lipid research (01-05-2000)
    “…Epidemiologic studies and in vitro experiments indicate that low density lipoprotein (LDL) subtypes differ concerning their atherogenic potential. Small, dense…”
    Get full text
    Journal Article
  16. 16

    First spin flipping of a stored spin-1 polarized beam by Morozov, V S, Etienne, Z B, Kandes, M C, Krisch, A D, Leonova, M A, Sivers, D W, Wong, V K, Yonehara, K, Anferov, V A, Meyer, H O, Schwandt, P, Stephenson, E J, von Przewoski, B

    Published in Physical review letters (21-11-2003)
    “…We recently studied spin flipping of a 270 MeV vertically polarized deuteron beam stored in the Indiana University Cyclotron Facility Cooler Ring. We…”
    Get full text
    Journal Article
  17. 17
  18. 18
  19. 19

    Short-term effects of statin therapy in patients with hyperlipoproteinemia after liver transplantation: results of a randomized cross-over trial by Zachoval, R, Gerbes, A.L, Schwandt, P, Parhofer, Klaus G

    Published in Journal of hepatology (01-07-2001)
    “…Background/Aims : Hyperlipoproteinemia is frequent following liver transplantation and may lead to atherosclerosis. Lipid-lowering agents may be useful, but…”
    Get full text
    Journal Article
  20. 20

    Effect of atorvastatin on low-density lipoprotein subtypes in patients with different forms of hyperlipoproteinemia and control subjects by Geiss, Hans C., Otto, Carsten, Schwandt, Peter, Parhofer, Klaus G.

    Published in Metabolism, clinical and experimental (01-08-2001)
    “…Atorvastatin is a potent hydroxy-methyl-glutaryl[ndash ]coenzyme A (HMG-CoA) reductase inhibitor that decreases low-density lipoprotein (LDL) cholesterol and…”
    Get full text
    Journal Article